Nautilus Biotechnology Inc

Nautilus Biotechnology, Inc. is a development stage life sciences company, which creates platform technology for quantifying and unlocking the complexity of the proteome. The company is headquartered in Seattle, Washington and currently employs 127 full-time employees. The company went IPO on 2020-08-07. The firm is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The firm is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The firm's platform end-to-end solution comprises the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs. Its platform consists of integrated reagents, fluidics, imaging, and ultra-dense nano-array flow cells.